CIK 0001604464 · Non-accelerated filer<br>Smaller reporting company
Atara Biotherapeutics, Inc.
Sign in to watch- Ticker
- ATRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 460920988
- Phone
- 805-623-4211
- Business address
- 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320
- 4 Open-market sale Chief Financial Officer sold 5,853 shares at $5.63 ($32,952)
- 4 Open-market sale SVP, GC & Secretary sold 3,223 shares at an average $5.32 ($17,134)
- 4 Open-market sale Chief Financial Officer sold 5,582 shares at an average $5.32 ($29,675)
- 4 Open-market sale EVP, Head of R&D sold 3,873 shares at $5.32 ($20,597)
- 4 Open-market sale President and CEO sold 13,913 shares at $5.32 ($73,962)
- 8-K Event Agreement ended
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 8-K Event Acquisition or sale completed
- SC 13G/A Stake Amended Statement of Ownership
- 4 Open-market sale Chief Financial Officer sold 3,763 shares at an average $9.86 ($37,090)
- 4 Open-market sale EVP, Head of R&D sold 2,221 shares at $9.86 ($21,890)
- 4 Grant or award Chief Commercial Officer acquired 45,533 shares (grant or award)
- 4 Open-market sale President and CEO sold 8,828 shares at $9.86 ($87,009)
- 4 Open-market sale SVP, GC & Secretary sold 2,577 shares at an average $9.86 ($25,400)
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
Page 18 of 57 · 1,133 filings